Cozen O’Connor filed a patent infringement suit on behalf of pharmaceutical manufacturer Endo Operations over Gland Pharma’s attempt to create a generic version of the patented hypotension medication Vasostrict. The claim, filed Tuesday in New Jersey federal court, claimed that Gland’s abbreviated new drug application submitted to the Food and Drug Administration was submitted before Endo’s patent for Vasostrict expired.

Takeaway: The lawsuit is an abbreviated new drug application, or ANDA, case, which is a highly active practice in New Jersey and elsewhere.